ClinicalTrials.gg
CompletedNCT05419401Updated Jul 22, 2022

A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

A Phase 1 interventional study of Capivasertib film-coated tablet, 200 mg and [14C]AZD5363 (Capivasertib) in Healthy Volunteer, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

The Sponsor is developing the test medicine, Capivasertib, for the potential treatment of primary breast and prostate cancer. This two-part healthy volunteer study will try to identify the absolute bioavailability (amount of the test medicine that enters the blood stream), mass balance recovery (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of the test medicine.

Read the detailed description

The Sponsor is developing the test medicine, Capivasertib, for the potential treatment of primary breast and prostate cancer. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably, causing a growth called a tumour. The cancerous cells can invade and destroy surrounding healthy tissue, including organs. The four most common types of cancer within the UK are: breast, lung, prostate and bowel cancer. This two-part healthy volunteer study will try to identify the absolute bioavailability (amount of the test medicine that enters the blood stream), mass balance recovery (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of the test medicine. Two out of three recipes of the test medicine are radiolabelled with carbon-14. 'Radiolabelled' means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body. This study will consist of two periods involving up to eight healthy male volunteers aged 30-65 and will take place at one non-NHS site. In Part 1, volunteers will receive a single dose of 2 non-radiolabelled oral tablets in the fasted state followed by an intravenous infusion (solution into the vein) of radiolabelled test medicine 1 hour 15 mins minutes later. Volunteers will be discharged from the clinical unit on Day 5. In Part 2, volunteers will receive a single oral dose of a radiolabelled oral solution in the fasted state. Volunteers will be discharged on Day 8, however may be required to remain at the clinical unit until Day 10 if the mass balance criteria have not been met by Day 8. Volunteers will receive a follow up phone call between Day 15 and Day 19. Volunteer's blood, urine and faeces will be taken throughout the study for analysis of the test medicine, radiation and for safety. Volunteers are expected to be involved in this study for approximately 9 weeks from screening to the follow-up call.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy volunteer
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Must be willing and able to communicate and participate in the whole study.
  • Healthy males aged 30 to 65 years inclusive at the time of signing informed consent.
  • Must be vasectomised (at least 6 months prior to screening) and must agree to adhere to the requirements of the study.
  • Have a (BMI) between 18.0 and 30.0 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive as measured at screening.
  • Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)
  • Provision of signed, written and dated informed consent for optional genetic research. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
  • History of any clinically significant disease or disorder (e.g. cardiovascular, pulmonary, GI (including but not limited to nausea and vomiting, malabsorption syndrome, chronic GI diseases, previous cholecystectomy, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib), liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment, skin abnormalities and glucose metabolism abnormalities) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the ADME of drugs.
  • History of latent or chronic infections (e.g. tuberculosis, recurrent sinusitis, genital herpes, urinary tract infections) or at risk of infection (surgery, trauma or significant infection within previous 90 days, history of skin abscesses within previous 90 days).
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to capivasertib. Hay fever is allowed unless it is active
  • Any known or suspected hypersensitivity or to the components of the study drug, capivasertib, judged to be clinically relevant by the investigator.
  • History of severe COVID-19 (e.g. hospitalisation, extracorporeal membrane oxygenation, mechanically ventilated) in the last 6 months.
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
  • Any clinically significant abnormal findings in vital signs, at screening or pre-dose, as judged by the investigator.
  • >450 msec or QT >500 msec or other clinically significant abnormality, as judged by the investigator, at screening or pre-dose, or a history of additional risk factors for Torsades de Points (e.g. heart failure, hypokalaemia, family history of long QT syndrome), which in the opinion of the Investigator may put the volunteer at risk.
  • Evidence of current SARS-CoV-2 infection within 2 weeks of first IMP administration.
  • Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the investigator
  • Total (TBL) ≥1.5×the or ≥3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia)
  • Clinically significant abnormal fasting blood glucose or triglycerides at screening.
  • Any positive result on screening for serum surface antigen (HBsAg), virus antibody (HCV Ab), and (HIV) 1 and 2 antibody.
  • Evidence of renal impairment at screening, as indicated by an estimated of \<70 mL/min using the Cockcroft-Gault equation.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer. Note: subjects consented and screened, but not randomised in this study or a previous Phase I study, are not excluded.
  • Subjects who report to have previously received capivasertib.
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
  • Subjects who have been administered IMP in an ADME study in the last 12 months.
  • Plasma donation within 1 month of screening or any donation or loss (e.g. due to trauma or surgery) of >500 mL blood within the previous 3 months or 1350 mL of blood in 12 months prior to current study.
  • Use of any prescribed or non-prescribed medication including antacids, analgesics (other than 4 g of paracetamol/acetaminophen per day), herbal remedies, vitamins, and minerals during the two weeks prior to the first administration of IMP or longer if the medication has a long half-life. COVID-19 vaccines are accepted concomitant medications. Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the is such that no pharmacodynamic (PD) activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardise the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study
  • Use of drugs which are strong inhibitors or inducers of or drugs that are sensitive to inhibition of CYP3A4 within 2 weeks prior to the first administration of IMP
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks or 5 half-lives, whichever is longer, prior to the first administration of IMP.
  • Known or suspected history of alcohol or drug abuse in the past 2 years or excessive intake of alcohol (>21 units per week [1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type]) or as judged by the investigator.
  • A confirmed positive alcohol breath test at screening or admission.
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 6 months prior to screening.
  • A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
  • Confirmed positive screen for drugs of abuse at screening or admission to the clinical unit.
  • Excessive intake of caffeine-containing drinks or food (e.g. coffee, tea, chocolate) as judged by the investigator. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day (e.g. >5 cups of coffee) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the clinical unit.
  • Subjects with pregnant or lactating partners.
  • Planned in-patient surgery, dental procedure or hospitalisation during the study.
  • Involvement of any AstraZeneca AB, Quotient or study site employee or their close relatives.
  • Subjects who are regularly exposed to the risk of COVID-19 infection as per of their daily life (e.g. health care professionals working in COVID-19 wards or at emergency departments).
  • Judgment by the investigator that the volunteer should not participate in the study if they have any ongoing or recent (i.e. during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Subjects who cannot communicate reliably with the investigator.
  • Vulnerable subjects, e.g. kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  • Failure to satisfy the investigator of fitness to participate for any other reason.

In addition, the following is considered a criterion for the exclusion from the optional genetic component of the study:

  • Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection or previous bone marrow transplant.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Capivasertib

    film-coated tablet, 200 mg

    Drug: Capivasertib film-coated tablet, 200 mg

  • Experimental
    [14C]AZD5363 (Capivasertib)

    Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) and Oral Solution, 400 mg (NMT 4.8 MBq)

    Drug: [14C]AZD5363 (Capivasertib)

Interventions

  • DrugCapivasertib film-coated tablet, 200 mg

    400mg dose, oral, fasted

  • Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability (F)

    Absolute bioavailability (F) of oral capivasertib compared to \[14C\]-capivasertib (part 1)

    Time frame: Plasma sample collection from pre-dose to 72 hours post dose

  2. tmax

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (part 1)

    Time frame: Plasma sample collection from pre-dose to 72 hours post dose

  3. Cmax

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (part 1)

    Time frame: Plasma samples collection from pre-dose to 72 hours post dose

  4. AUC0-t

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (Part 1)

    Time frame: Plasma samples collection from pre-dose to 72 hours post dose

  5. AUC0-inf

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (Part 1)

    Time frame: Plasma samples collection from pre-dose to 72 hours post dose

  6. t1/2

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (Part 1)

    Time frame: Plasma samples collection from pre-dose to 72 hours post dose

  7. λz

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (Part 1)

    Time frame: Plasma samples collection from pre-dose to 72 hours post dose

  8. CL/F

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (Part 1)

    Time frame: Plasma samples collection from pre-dose to 72 hours post dose

  9. Vz/F

    PK of capivasertib and \[14C\]AZD5363 (capivasertib) in plasma (Part 1)

    Time frame: Plasma samples collection from pre-dose to 72 hours post dose

  10. tmax

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose to 168 hours post dose

  11. Cmax

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose to 168 hours post dose

  12. AUC0-t

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose to 168 hours post dose

  13. AUC0-inf

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  14. t1/2

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  15. λz

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  16. CL/F

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  17. Vz/F

    PK (plasma) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose until 168 hours post-dose

  18. CLR

    PK (plasma and urine) and total radioactivity (whole blood and plasma) of capivasertib (Part 2)

    Time frame: Plasma sample collection from pre-dose to 72 hours post dose and urine samples collected from pre-dose until 168 hours post-dose

  19. CumAe

    Mass balance recovery of \[14C\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  20. Cum%Ae

    Mass balance recovery of \[14C\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  21. Ae

    Mass balance recovery of \[14C\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)

    Time frame: Urine and faecal sample collection from pre-dose until 168 hours post-dose

  22. %Ae

    Mass balance recovery of \[14C\]AZD5365 (capivasertib) from urine and faecal samples (Part 2)

    Time frame: Urine and faecal sample collection from pre-dose until 168 hours post-dose

  23. Blood:plasma concentration ratios

    Blood:plasma concentration ratios of total radioactivity (Part 2)

    Time frame: Whole blood samples collected up to 24 hours post dose. Plasma sample collection from pre-dose until 72 hours post-dose

Secondary outcomes

  1. Number of subjects with treatment-related adverse events

    To provide additional safety and tolerability information for capivasertib by assessing the incidence of AEs (Part 1 and 2)

    Time frame: Through study duration, an average of 9 weeks.

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jul 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2022
First posted
Jun 15, 2022
StartActual
Apr 11, 2022
Primary completionActual
Jul 12, 2022
CompletionActual
Jul 12, 2022
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05419401
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Jun 15, 2022
Start date
Apr 11, 2022
Primary completion
Jul 12, 2022
Completion
Jul 12, 2022
Last update
Jul 22, 2022

Study contacts

Sharan Sidhu, MBChB, BAO, MRCS, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion